|Author(s)/Faculty: Rishi P. Singh, MD; W. Lloyd Clark, MD|
|Release Date: 12/22/2020||Expiration Date: 12/21/2021|
|Credit Type: CME / ABO MOC||Number of Credits: 1|
|Content Type: Video||Provider: |
|Optimal integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapies into treatment protocols for patients with diabetic retinopathy (DR) have demonstrated delayed disease progression, yet most patients with DR are currently not receiving these medications. Pinnacle clinical studies have identified that early intervention in DR not only reduces vision-threatening complications, but significantly slows disease progression, with the potential to significantly improve DR severity scores. Within this CME activity, experts in the field examine the latest clinical data supporting the utilization of anti-VEGF therapies early in the disease process as well as compare evidence-based anti-VEGF injection protocols for their ability to achieve long-term benefits in patients with proliferative and non-proliferative DR.